{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:19:36Z","timestamp":1789172376088,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The trajectory of B cell development goes through subsequent steps governed by complex genetic programs, strictly regulated by multiple transcription factors. Interferon regulatory factor 4 (IRF4) regulates key points from pre-B cell development and receptor editing to germinal center formation, class-switch recombination and plasma cell differentiation. The pleiotropic ability of IRF4 is mediated by its \u201ckinetic control\u201d, allowing different IRF4 expression levels to activate distinct genetic programs due to modulation of IRF4 DNA-binding affinity. IRF4 is implicated in B cell malignancies, acting both as tumor suppressor and as tumor oncogene in different types of precursors and mature B cell neoplasia. Here, we summarize the complexity of IRF4 functions related to different DNA-binding affinity, multiple IRF4-specific target DNA motif, and interactions with transcriptional partners. Moreover, we describe the unique role of IRF4 in acute leukemias and B cell mature neoplasia, focusing on pathogenetic implications and possible therapeutic strategies in multiple myeloma and chronic lymphocytic leukemia.<\/jats:p>","DOI":"10.1007\/s10238-022-00968-0","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T14:02:31Z","timestamp":1670680951000},"page":"1171-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The dynamic functions of IRF4 in B cell malignancies"],"prefix":"10.1007","volume":"23","author":[{"given":"Rossana","family":"Maffei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Fiorcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Giacinto","family":"Atene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Mesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lagreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Barozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Nasillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Trenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"issue":"46","key":"968_CR1","doi-asserted-by":"publisher","first-page":"27779","DOI":"10.1074\/jbc.M115.678789","volume":"290","author":"SG Remesh","year":"2015","unstructured":"Remesh SG, Santosh V, Escalante CR. Structural studies of IRF4 Reveal a flexible autoinhibitory region and a compact linker domain. J Biol Chem. 2015;290(46):27779\u201390. https:\/\/doi.org\/10.1074\/jbc.M115.678789.","journal-title":"J Biol Chem"},{"key":"968_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1287","author":"S Sundararaj","year":"2021","unstructured":"Sundararaj S, Seneviratne S, Williams SJ, Enders A, Casarotto MG. Structural determinants of the IRF4\/DNA homodimeric complex. Nucleic Acids Res. 2021. https:\/\/doi.org\/10.1093\/nar\/gkaa1287.","journal-title":"Nucleic Acids Res"},{"issue":"5299","key":"968_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1126\/science.275.5299.540","volume":"275","author":"HW Mittr\u00fccker","year":"1997","unstructured":"Mittr\u00fccker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF\/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540\u20133. https:\/\/doi.org\/10.1126\/science.275.5299.540.","journal-title":"Science"},{"issue":"2","key":"968_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nri1780","volume":"6","author":"T Nagasawa","year":"2006","unstructured":"Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol. 2006;6(2):107\u201316. https:\/\/doi.org\/10.1038\/nri1780.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"968_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1101\/gad.9.11.1377","volume":"9","author":"CF Eisenbeis","year":"1995","unstructured":"Eisenbeis CF, Singh H, Storb U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 1995;9(11):1377\u201387. https:\/\/doi.org\/10.1101\/gad.9.11.1377.","journal-title":"Genes Dev"},{"issue":"1","key":"968_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1128\/mcb.12.1.368-378.1992","volume":"12","author":"JM Pongubala","year":"1992","unstructured":"Pongubala JM, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA, Atchison ML. PU.1 recruits a second nuclear factor to a site important for immunoglobulin kappa 3\u2032 enhancer activity. Mol Cell Biol. 1992;12(1):368\u201378. https:\/\/doi.org\/10.1128\/mcb.12.1.368-378.1992.","journal-title":"Mol Cell Biol."},{"issue":"4","key":"968_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/emboj\/18.4.977","volume":"18","author":"AL Brass","year":"1999","unstructured":"Brass AL, Zhu AQ, Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J. 1999;18(4):977\u201391. https:\/\/doi.org\/10.1093\/emboj\/18.4.977.","journal-title":"EMBO J"},{"issue":"5","key":"968_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S1097-2765(02)00703-7","volume":"10","author":"CR Escalante","year":"2002","unstructured":"Escalante CR, Brass AL, Pongubala JMR, et al. Crystal structure of PU.1\/IRF-4\/DNA ternary complex. Mol Cell. 2002;10(5):1097\u2013105.","journal-title":"Mol Cell"},{"issue":"14","key":"968_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1101\/gad.1104803","volume":"17","author":"R Lu","year":"2003","unstructured":"Lu R, Medina KL, Lancki DW, Singh H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev. 2003;17(14):1703\u20138. https:\/\/doi.org\/10.1101\/gad.1104803.","journal-title":"Genes Dev"},{"issue":"11","key":"968_CR10","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.4049\/jimmunol.177.11.7898","volume":"177","author":"S Ma","year":"2006","unstructured":"Ma S, Turetsky A, Trinh L, Lu R. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development. J Immunol. 2006;177(11):7898\u2013904. https:\/\/doi.org\/10.4049\/jimmunol.177.11.7898.","journal-title":"J Immunol"},{"issue":"6","key":"968_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ni.1612","volume":"9","author":"RH Amin","year":"2008","unstructured":"Amin RH, Schlissel MS. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol. 2008;9(6):613\u201322. https:\/\/doi.org\/10.1038\/ni.1612.","journal-title":"Nat Immunol"},{"key":"968_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1667","author":"HS Dengler","year":"2008","unstructured":"Dengler HS, Baracho GV, Omori SA, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008. https:\/\/doi.org\/10.1038\/ni.1667.","journal-title":"Nat Immunol"},{"issue":"17","key":"968_CR13","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1128\/MCB.00224-10","volume":"30","author":"S Ma","year":"2010","unstructured":"Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010;30(17):4149\u201358. https:\/\/doi.org\/10.1128\/MCB.00224-10.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"968_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.immuni.2007.12.019","volume":"28","author":"K Johnson","year":"2008","unstructured":"Johnson K, Hashimshony T, Sawai CM, et al. Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity. 2008;28(3):335\u201345. https:\/\/doi.org\/10.1016\/j.immuni.2007.12.019.","journal-title":"Immunity"},{"issue":"12","key":"968_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2136","volume":"12","author":"M Mandal","year":"2011","unstructured":"Mandal M, Powers SE, Maienschein-Cline M, et al. Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol. 2011;12(12):1212\u201320. https:\/\/doi.org\/10.1038\/ni.2136.","journal-title":"Nat Immunol"},{"issue":"10","key":"968_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41590-019-0468-0","volume":"20","author":"M Mandal","year":"2019","unstructured":"Mandal M, Okoreeh MK, Kennedy DE, et al. CXCR4 signaling directs Igk recombination and the molecular mechanisms of late B lymphopoiesis. Nat Immunol. 2019;20(10):1393\u2013403. https:\/\/doi.org\/10.1038\/s41590-019-0468-0.","journal-title":"Nat Immunol"},{"key":"968_CR17","doi-asserted-by":"publisher","first-page":"779085","DOI":"10.3389\/fimmu.2021.779085","volume":"12","author":"K Ottens","year":"2021","unstructured":"Ottens K, Satterthwaite AB. IRF4 has a unique role in early B cell development and acts prior to CD21 expression to control marginal zone B cell numbers. Front Immunol. 2021;12:779085. https:\/\/doi.org\/10.3389\/fimmu.2021.779085.","journal-title":"Front Immunol"},{"issue":"1","key":"968_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.V91.1.22","volume":"91","author":"M Schmidt","year":"1998","unstructured":"Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91(1):22\u20139.","journal-title":"Blood"},{"issue":"21","key":"968_CR19","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1093\/nar\/gki1001","volume":"33","author":"CA Ortmann","year":"2005","unstructured":"Ortmann CA, Burchert A, H\u00f6lzle K, et al. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 2005;33(21):6895\u2013905. https:\/\/doi.org\/10.1093\/nar\/gki1001.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"968_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4049\/jimmunol.174.1.367","volume":"174","author":"F Klein","year":"2005","unstructured":"Klein F, Feldhahn N, Mooster JL, et al. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2005;174(1):367\u201375. https:\/\/doi.org\/10.4049\/jimmunol.174.1.367.","journal-title":"J Immunol"},{"issue":"9","key":"968_CR21","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1182\/blood-2007-10-117838","volume":"112","author":"J Acquaviva","year":"2008","unstructured":"Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 2008;112(9):3798\u2013806. https:\/\/doi.org\/10.1182\/blood-2007-10-117838.","journal-title":"Blood"},{"issue":"7","key":"968_CR22","doi-asserted-by":"publisher","first-page":"e22628","DOI":"10.1371\/journal.pone.0022628","volume":"6","author":"S Pathak","year":"2011","unstructured":"Pathak S, Ma S, Trinh L, et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS ONE. 2011;6(7):e22628. https:\/\/doi.org\/10.1371\/journal.pone.0022628.","journal-title":"PLoS ONE"},{"issue":"15","key":"968_CR23","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1182\/blood-2009-07-234559","volume":"116","author":"SH Jo","year":"2010","unstructured":"Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood. 2010;116(15):2759\u201367. https:\/\/doi.org\/10.1182\/blood-2009-07-234559.","journal-title":"Blood"},{"issue":"6","key":"968_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/leu.2016.27","volume":"30","author":"SHM Pang","year":"2016","unstructured":"Pang SHM, Minnich M, Gangatirkar P, et al. PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia. Leukemia. 2016;30(6):1375\u201387. https:\/\/doi.org\/10.1038\/leu.2016.27.","journal-title":"Leukemia"},{"key":"968_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01005-z","author":"D Das Gupta","year":"2022","unstructured":"Das Gupta D, Paul C, Samel N, et al. IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity. Cell Death Differ. 2022. https:\/\/doi.org\/10.1038\/s41418-022-01005-z.","journal-title":"Cell Death Differ"},{"issue":"9","key":"968_CR26","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2014-02-553842","volume":"124","author":"AYL So","year":"2014","unstructured":"So AYL, Sookram R, Chaudhuri AA, et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood. 2014;124(9):1502\u201312. https:\/\/doi.org\/10.1182\/blood-2014-02-553842.","journal-title":"Blood"},{"issue":"10","key":"968_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.it.2008.07.006","volume":"29","author":"R Lu","year":"2008","unstructured":"Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008;29(10):487\u201392. https:\/\/doi.org\/10.1016\/j.it.2008.07.006.","journal-title":"Trends Immunol"},{"issue":"7","key":"968_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/ni1357","volume":"7","author":"U Klein","year":"2006","unstructured":"Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773\u201382. https:\/\/doi.org\/10.1038\/ni1357.","journal-title":"Nat Immunol"},{"issue":"5","key":"968_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.smim.2011.08.010","volume":"23","author":"SL Nutt","year":"2011","unstructured":"Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The genetic network controlling plasma cell differentiation. Semin Immunol. 2011;23(5):341\u20139. https:\/\/doi.org\/10.1016\/j.smim.2011.08.010.","journal-title":"Semin Immunol"},{"issue":"5","key":"968_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.immuni.2013.04.009","volume":"38","author":"K Ochiai","year":"2013","unstructured":"Ochiai K, Maienschein-Cline M, Simonetti G, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity. 2013;38(5):918\u201329. https:\/\/doi.org\/10.1016\/j.immuni.2013.04.009.","journal-title":"Immunity"},{"issue":"2","key":"968_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2006.07.009","volume":"25","author":"R Sciammas","year":"2006","unstructured":"Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25(2):225\u201336. https:\/\/doi.org\/10.1016\/j.immuni.2006.07.009.","journal-title":"Immunity"},{"issue":"2","key":"968_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.leu.2404895","volume":"22","author":"D Heintel","year":"2008","unstructured":"Heintel D, Zojer N, Schreder M, et al. Expression of MUM1\/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2008;22(2):441\u20135. https:\/\/doi.org\/10.1038\/sj.leu.2404895.","journal-title":"Leukemia"},{"issue":"2","key":"968_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng1097-226","volume":"17","author":"S Iida","year":"1997","unstructured":"Iida S, Rao PH, Butler M, et al. Deregulation of MUM1\/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17(2):226\u201330. https:\/\/doi.org\/10.1038\/ng1097-226.","journal-title":"Nat Genet"},{"issue":"11","key":"968_CR34","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/sj.leu.2401563","volume":"13","author":"S Yoshida","year":"1999","unstructured":"Yoshida S, Nakazawa N, Iida S, et al. Detection of MUM1\/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999;13(11):1812\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2401563.","journal-title":"Leukemia"},{"issue":"1","key":"968_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101. https:\/\/doi.org\/10.1016\/j.ccr.2013.12.015.","journal-title":"Cancer Cell"},{"issue":"7201","key":"968_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NCT, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226\u201331. https:\/\/doi.org\/10.1038\/nature07064.","journal-title":"Nature"},{"key":"968_CR37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.6.3125","author":"I Gy\u00f6ry","year":"2003","unstructured":"Gy\u00f6ry I, Fej\u00e9r G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol. 2003. https:\/\/doi.org\/10.4049\/jimmunol.170.6.3125.","journal-title":"J Immunol"},{"issue":"11","key":"968_CR38","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/leu.2015.124","volume":"29","author":"E Morelli","year":"2015","unstructured":"Morelli E, Leone E, Cantafio MEG, et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29(11):2173\u201383. https:\/\/doi.org\/10.1038\/leu.2015.124.","journal-title":"Leukemia"},{"issue":"7","key":"968_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","volume":"35","author":"PL Fedele","year":"2021","unstructured":"Fedele PL, Liao Y, Gong JN, et al. The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia. 2021;35(7):2114\u20138. https:\/\/doi.org\/10.1038\/s41375-020-01078-0.","journal-title":"Leukemia"},{"issue":"4","key":"968_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","volume":"28","author":"PK Mondala","year":"2021","unstructured":"Mondala PK, Vora AA, Zhou T, et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell. 2021;28(4):623-636.e9. https:\/\/doi.org\/10.1016\/j.stem.2020.12.017.","journal-title":"Cell Stem Cell"},{"issue":"6769","key":"968_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311. https:\/\/doi.org\/10.1038\/35000501.","journal-title":"Nature"},{"issue":"17","key":"968_CR42","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.1732008100","volume":"100","author":"G Wright","year":"2003","unstructured":"Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991\u20136. https:\/\/doi.org\/10.1073\/pnas.1732008100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"968_CR43","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347. https:\/\/doi.org\/10.1056\/NEJMoa012914.","journal-title":"N Engl J Med"},{"issue":"4","key":"968_CR44","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/MOH.0b013e3283623d7f","volume":"20","author":"L Pasqualucci","year":"2013","unstructured":"Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol. 2013;20(4):336\u201344. https:\/\/doi.org\/10.1097\/MOH.0b013e3283623d7f.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"968_CR45","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390. https:\/\/doi.org\/10.1038\/s41591-018-0016-8.","journal-title":"Nat Med"},{"issue":"15","key":"968_CR46","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1801445.","journal-title":"N Engl J Med"},{"issue":"20","key":"968_CR47","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759\u201371. https:\/\/doi.org\/10.1182\/blood.2019003535.","journal-title":"Blood"},{"issue":"9","key":"968_CR48","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","volume":"106","author":"S Bea","year":"2005","unstructured":"Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183\u201390. https:\/\/doi.org\/10.1182\/blood-2005-04-1399.","journal-title":"Blood"},{"issue":"6","key":"968_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL, Emre NCT, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723\u201337. https:\/\/doi.org\/10.1016\/j.ccr.2012.05.024.","journal-title":"Cancer Cell"},{"issue":"7","key":"968_CR50","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"issue":"4","key":"968_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1182\/blood.2019002699","volume":"135","author":"JE Ramis-Zaldivar","year":"2020","unstructured":"Ramis-Zaldivar JE, Gonzalez-Farr\u00e9 B, Balagu\u00e9 O, et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020;135(4):274\u201386. https:\/\/doi.org\/10.1182\/blood.2019002699.","journal-title":"Blood"},{"issue":"10","key":"968_CR52","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/ng.219","volume":"40","author":"MC Di Bernardo","year":"2008","unstructured":"Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10):1204\u201310. https:\/\/doi.org\/10.1038\/ng.219.","journal-title":"Nat Genet"},{"issue":"4","key":"968_CR53","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/1055-9965.EPI-09-1217","volume":"19","author":"SL Slager","year":"2010","unstructured":"Slager SL, Goldin LR, Strom SS, et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomark Prev. 2010;19(4):1098\u2013102. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-1217.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"968_CR54","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/hmg\/ddq044","volume":"19","author":"D Crowther-Swanepoel","year":"2010","unstructured":"Crowther-Swanepoel D, Broderick P, Ma Y, et al. Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet. 2010;19(9):1840\u20135. https:\/\/doi.org\/10.1093\/hmg\/ddq044.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"968_CR55","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2011-04-350579","volume":"118","author":"V Havelange","year":"2011","unstructured":"Havelange V, Pekarsky Y, Nakamura T, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011;118(10):2827\u20139. https:\/\/doi.org\/10.1182\/blood-2011-04-350579.","journal-title":"Blood"},{"issue":"7574","key":"968_CR56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525\u201330. https:\/\/doi.org\/10.1038\/nature15395.","journal-title":"Nature"},{"issue":"7574","key":"968_CR57","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519\u201324. https:\/\/doi.org\/10.1038\/nature14666.","journal-title":"Nature"},{"issue":"3","key":"968_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2017.291","volume":"32","author":"F Nadeu","year":"2018","unstructured":"Nadeu F, Clot G, Delgado J, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018;32(3):645\u201353. https:\/\/doi.org\/10.1038\/leu.2017.291.","journal-title":"Leukemia"},{"issue":"10","key":"968_CR59","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2011-04-350579","volume":"118","author":"V Havelange","year":"2011","unstructured":"Havelange V, Pekarsky Y, Nakamura T, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011;118(10):2827\u20139. https:\/\/doi.org\/10.1182\/blood-2011-04-350579.","journal-title":"Blood"},{"issue":"7574","key":"968_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525\u201330. https:\/\/doi.org\/10.1038\/nature15395.","journal-title":"Nature"},{"issue":"17","key":"968_CR61","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1158\/1078-0432.CCR-15-3103","volume":"22","author":"NA Amin","year":"2016","unstructured":"Amin NA, Seymour E, Saiya-Cork K, Parkin B, Shedden K, Malek SN. A quantitative analysis of subclonal and clonal gene mutations before and after therapy in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22(17):4525\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3103.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"968_CR62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2017.291","volume":"32","author":"F Nadeu","year":"2018","unstructured":"Nadeu F, Clot G, Delgado J, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018;32(3):645\u201353. https:\/\/doi.org\/10.1038\/leu.2017.291.","journal-title":"Leukemia"},{"issue":"7574","key":"968_CR63","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519\u201324. https:\/\/doi.org\/10.1038\/nature14666.","journal-title":"Nature"},{"issue":"8","key":"968_CR64","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","volume":"28","author":"F Nadeu","year":"2022","unstructured":"Nadeu F, Royo R, Massoni-Badosa R, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022;28(8):1662\u201371. https:\/\/doi.org\/10.1038\/s41591-022-01927-8.","journal-title":"Nat Med"},{"issue":"12","key":"968_CR65","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","volume":"1","author":"S Kadri","year":"2017","unstructured":"Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1(12):715\u201327. https:\/\/doi.org\/10.1182\/bloodadvances.2016003632.","journal-title":"Blood Adv"},{"issue":"13","key":"968_CR66","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","volume":"78","author":"T Vaisitti","year":"2018","unstructured":"Vaisitti T, Braggio E, Allan JN, et al. Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses. Cancer Res. 2018;78(13):3413\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-4004.","journal-title":"Cancer Res"},{"issue":"5","key":"968_CR67","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hon.2915","volume":"39","author":"S Benatti","year":"2021","unstructured":"Benatti S, Atene CG, Fiorcari S, et al. IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. Hematol Oncol. 2021;39(5):707\u201311. https:\/\/doi.org\/10.1002\/hon.2915.","journal-title":"Hematol Oncol"},{"issue":"20","key":"968_CR68","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood.2019000973","volume":"134","author":"D Asslaber","year":"2019","unstructured":"Asslaber D, Qi Y, Maeding N, et al. B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion. Blood. 2019;134(20):1717\u201329. https:\/\/doi.org\/10.1182\/blood.2019000973.","journal-title":"Blood"},{"issue":"13","key":"968_CR69","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1182\/blood-2002-01-0104","volume":"100","author":"CC Chang","year":"2002","unstructured":"Chang CC, Lorek J, Sabath DE, et al. Expression of MUM1\/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood. 2002;100(13):4671\u20135. https:\/\/doi.org\/10.1182\/blood-2002-01-0104.","journal-title":"Blood"},{"issue":"13","key":"968_CR70","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1084\/jem.20131026","volume":"210","author":"G Simonetti","year":"2013","unstructured":"Simonetti G, Carette A, Silva K, et al. IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity. J Exp Med. 2013;210(13):2887\u2013902. https:\/\/doi.org\/10.1084\/jem.20131026.","journal-title":"J Exp Med"},{"issue":"5","key":"968_CR71","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41375-018-0296-5","volume":"33","author":"S Fiorcari","year":"2019","unstructured":"Fiorcari S, Benatti S, Zucchetto A, et al. Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. Leukemia. 2019;33(5):1278\u2013302. https:\/\/doi.org\/10.1038\/s41375-018-0296-5.","journal-title":"Leukemia"},{"issue":"5","key":"968_CR72","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41375-021-01178-5","volume":"35","author":"R Maffei","year":"2021","unstructured":"Maffei R, Fiorcari S, Benatti S, et al. IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. Leukemia. 2021;35(5):1330\u201343. https:\/\/doi.org\/10.1038\/s41375-021-01178-5.","journal-title":"Leukemia"},{"issue":"16","key":"968_CR73","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1182\/blood-2013-03-492769","volume":"122","author":"V Shukla","year":"2013","unstructured":"Shukla V, Ma S, Hardy RR, Joshi SS, Lu R. A role for IRF4 in the development of CLL. Blood. 2013;122(16):2848\u201355. https:\/\/doi.org\/10.1182\/blood-2013-03-492769.","journal-title":"Blood"},{"issue":"37","key":"968_CR74","doi-asserted-by":"publisher","first-page":"26430","DOI":"10.1074\/jbc.M113.475913","volume":"288","author":"S Ma","year":"2013","unstructured":"Ma S, Shukla V, Fang L, Gould KA, Joshi SS, Lu R. Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4. J Biol Chem. 2013;288(37):26430\u201340. https:\/\/doi.org\/10.1074\/jbc.M113.475913.","journal-title":"J Biol Chem"},{"issue":"16","key":"968_CR75","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1182\/blood-2013-08-521120","volume":"122","author":"Y Zhong","year":"2013","unstructured":"Zhong Y, Byrd JC. IRF4(\u2212\/\u2212)Vh11 mice: a novel mouse model of CLL. Blood. 2013;122(16):2769\u201370. https:\/\/doi.org\/10.1182\/blood-2013-08-521120.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00968-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00968-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00968-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T14:19:59Z","timestamp":1690813199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00968-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00968-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}